Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Drug Use Limits Benefits of Surgery

September 8, 2015 By Elsevier

Injection drug users have a higher risk of needing another operation or dying following the procedure. Injection drug users who undergo surgery for infective endocarditis (IE) have a significantly higher risk of reoperation or death between three and six months after surgery compared to patients who develop endocarditis who are not IV drug abusers, according to an article in the September 2015 issue of the Annals of Thoracic Surgery.

IE is an infection caused by bacteria that enter the bloodstream and get into the heart lining, a heart valve, or a blood vessel. Previously, the main risk factor for IE was rheumatic heart disease but recent research has shown that other risk factors have gained prominence, including injection drug use (IDU), prosthetic valve infection, degenerative valvular disease, and hemodialysis.

“Injection drug use is a growing public health problem, especially among young adults between 20 and 35 years of age,” said Nabin K. Shrestha, MD, MPH, from the Cleveland Clinic, who led the study. “Injecting drugs into the bloodstream carries with it the potential for inadvertently introducing microorganisms into the bloodstream, which can settle on heart valves and cause IE.”

Dr. Shrestha and colleagues identified 536 patients who underwent surgery for IE at Cleveland Clinic between July 2007 and July 2012. Of those, 41 (8 percent) were active injection drug abusers.

They found that between three and six months after surgery, injection drug abusers had 10 times the risk of death or reoperation for IE than the patients who did not inject drugs. Before three months and after six months, however, all patients appeared to have similar risk for death or reoperation.

The researchers suggested that the timeframe for the increased risk was related to ongoing injection drug abuse that probably resumed soon after patients were discharged from the hospital; consequences started to become apparent at three months after surgery.

“A major limitation of current medical care for patients with IDU is that appropriate treatment for addiction is very difficult to come by due to a lack of providers or facilities or the lack of insurance or other means to pay for the scarce resources that may be available,” explained Dr. Shrestha. “Our hope is that this study can help patients with IDU and their doctors understand the magnitude of risk for endocarditis relapse during this time period and convince policy makers that IE treatment without adequately addressing the underlying addiction in patients with IDU prevents achieving outcomes that should otherwise be attainable.”

Relevancy of Research as Substance Abuse Increases

In an invited commentary in the same issue of The Annals, Gabriel Aldea, MD, from the University of Washington in Seattle, discussed the relevancy of the research by Dr. Shrestha and colleagues noting data from the National Institutes of Health that shows substance abuse and the use of intravenous drugs in the United States increased dramatically in the past decade.

“The researchers’ last point is, in my opinion, the most relevant,” added Dr. Aldea. “The current fractured structure and silos between acute and chronic health care and social services leads to an inability to bridge the ‘treatment gap’ between the urgent symptoms of a disease and its underlying cause. Until addiction therapy is recognized as a critical component of care for patients with IDU, these sobering and disappointing long-term results are unlikely to improve. “

Related Articles Read More >

An illustration showing the Artedrone Sasha thrombectomy catheter approaching a blood clot.
This microrobot system is designed to float inside a stroke patient for autonomous thrombectomy
A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
The top nitinol cardiac medtech news of 2025 (so far)
A photo showing the Dualto Energy System's modular design with two generators stacked for two users at a time.
What J&J MedTech’s new Dualto says about the OR of the future — and Ottava
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe